In contrast, high glucose stimulation does not alter EVA1A RNA levels (Fig. S13B), suggesting that EVA1A expression specifically responds to circulating lipids rather than common sugars, despite the potential development of hyperglycemia and insulin resistance in advanced MASLD stages. The gene discussed is EVA1A; the disease is metabolic dysfunction-associated steatotic liver disease.